 Shares of Reata Pharmaceuticals Inc. RETA, 3.01 were up 2.4 in trading on Thursday after the company said the Food and Drug Administration granted priority review to the companys experimental treatment for Friedreichs ataxia, a rare nervous system disease. The regulator is now set to make a decision on omaveloxolone by Nov. 30. 